A Rapid, Culture-Free Method to Determine 50% Neutralization Titer (NT50) Using the ACE2-Competitive Bio-Plex Pro SARS-CoV-2 Neutralization Antibody Assay
Presented by: Kenneth Oh, PhD, Collaborations, Applications, and New Technology Senior Global Manager
Kelly King, PhD, Field Application Specialist II
Brad VanderWielen, PhD, Field Application Specialist II
Candice Cox, Global Marketing Manager, Immunoassays
View on demand
Emerging reports from the COVID 19 pandemic include a spectrum of patient symptoms due to the host immune response. In this webinar, Bio-Rad scientists discuss early research and nascent hypotheses about the pathophysiology of SARS CoV 2–induced COVID 19 disease by evaluating cytokine and chemokine profiles, the role of chronic inflammation in comorbidities, and the arc of immune resolution of historical virulent pathogens, such as SARS and MERS.